Please login to the form below

Not currently logged in
Email:
Password:

John Wilkinson steps down as Eucomed chief executive

Will be replaced by Luciano Cattani on interim basis as medical technology body sets to merge with the EDMA

John Wilkinson has left his position as chief executive of Eucomed and will be replaced by Luciano Cattani.

Cattani will lead the European medical technology body on an interim basis ahead of the organisation's plans to join forces in a united industry federation with the in vitro diagnostics association, the European Diagnostic Manufacturers Association (EDMA) under a single chief executive. 

Luciano Cattani - Eucomed
Luciano Cattani

Wilkinson, who spent three years in charge of Eucomed, originally announced his attention to step down in June, 2011.

During his time as head of the organisation, he led the development of a five-year strategy for the industry, including a commitment to value based innovation.

Plans to enforce a system to review and approve third-party medical educational conferences in accordance with its Code of Practice were also created under Wilkinson's leadership.

His interim replacement, Cattani, has a long career in healthcare, including stints in general management at Pfizer, as well as serving as president, EMEA and group president, international at medical technology company Stryker.

His previous roles within Eucomed include board member and vice chairman.

Commenting on the appointment, Eucomed chair Guy Lebeau said: “I find it very gratifying to have the peace of mind and knowledge that for the next few months, Eucomed is in the hands of a man so ingrained in, passionate about and knowledgeable on our industry.”

18th January 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Red Health

Red Health was formed in 2007 to bring something fresh to the healthcare PR world. Our approach was simple –...

Latest intelligence

David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...
Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...

Infographics